The FDA has launched a safety investigation into Novartis’ gene therapy Zolgensma following reports of tumors in patients, as ...

Eli Lilly could soon see two label expansions for Foundayo, it’s oral GLP-1, in swift succession: In September, the drugmaker ...

Johnson & Johnson’s much-hyped Icotyde pill shows another biologic-like efficacy in inflammatory diseases, with a phase 3 win ...

Sticking by the strong relationship Moderna has fostered with the United Kingdom, the mRNA specialist is relocating its home base in the country to a different part of the capital.  | Sticking by the ...

After playing a key role in sparking a new era in cancer treatment through its work in antibody drug conjugates (ADCs), Daiichi Sankyo is pursuing an even bigger ambition: to shape what comes next in ...

Against a backdrop of repeated industry challenges in court, the Centers for Medicare and Medicaid Services (CMS) is locking ...

Amid surging sales of Rezdiffra, Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership ...

Alnylam Pharmaceuticals is seeking a new chief commercial officer as the biopharma announced that its six-year CCO veteran ...

AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...

In a major reshaping of the pharmaceutical contract manufacturing landscape, Lonza has struck a deal to acquire the CDMO ...

Karyopharm Therapeutics filed for Chapter 11 bankruptcy as part of a plan to merge with Irish hematology biotech, Ayrmid. Massachusetts-based Karyopharm’s financial woes came to a head in August, when ...

Merck & Co. is chasing the finish line with its eye on one prize: a world without cancer. | In “From Our Pipeline to the ...